Last updated: October 10, 2026
Advil Cold and Sinus is an over-the-counter combination product containing ibuprofen and pseudoephedrine hydrochloride. Its commercial position is supported by brand recognition, dual symptom relief, and Haleon’s retail distribution. Its principal risks are generic substitution, pseudoephedrine purchasing restrictions, retailer private-label competition, and limited pricing power. The product has no conventional biologic, biosimilar, or Orange Book exclusivity profile.
Haleon does not separately disclose revenue or operating profit for Advil Cold and Sinus. Financial analysis therefore depends on Haleon’s broader Advil and respiratory-health disclosures, retail sales data, pricing trends, and market-share indicators rather than audited product-level results.
What is Advil Cold and Sinus and how does the product work?
Advil Cold and Sinus generally combines:
| Active ingredient |
Typical U.S. strength |
Primary function |
| Ibuprofen |
200 mg |
Pain relief, fever reduction, anti-inflammatory activity |
| Pseudoephedrine hydrochloride |
30 mg |
Nasal decongestion |
The product is intended for temporary relief of sinus pressure, nasal congestion, headache, minor body aches, and fever associated with colds and sinus symptoms. Product configurations can vary by market and package format. U.S. liquid-gel and caplet products are sold through mass retailers, pharmacies, grocery stores, club stores, and e-commerce channels.
The combination gives Advil Cold and Sinus a functional distinction from single-ingredient ibuprofen products and from acetaminophen-based cold medicines. It competes directly with combination products containing acetaminophen, phenylephrine, chlorpheniramine, guaifenesin, or other cold and flu ingredients.
Who owns Advil Cold and Sinus and how is it commercialized?
Haleon owns the Advil brand following the 2022 separation of GSK’s consumer-health business. The company markets Advil within its over-the-counter pain-relief portfolio, alongside brands such as Voltaren, Panadol, and Excedrin in selected markets.
The commercial model has four main components:
- Brand-led consumer demand for Advil.
- Pharmacy and mass-retail distribution.
- Seasonal merchandising during the fall and winter respiratory season.
- Premium pricing relative to private-label ibuprofen and pseudoephedrine combinations.
Haleon’s annual reports identify Advil as a strategic consumer-health brand but do not provide a separate revenue line for Advil Cold and Sinus. Revenue is generally reported at broader geographic, category, or brand-family levels. [1]
What is the FDA regulatory status of Advil Cold and Sinus?
Advil Cold and Sinus is an OTC drug rather than a prescription product. Its active ingredients are regulated primarily through the FDA OTC monograph framework and applicable labeling requirements.
Ibuprofen is an established OTC analgesic and antipyretic. Oral pseudoephedrine is an established OTC nasal decongestant, but its retail distribution is subject to federal and state controls because pseudoephedrine can be diverted for illicit methamphetamine production.
The product’s regulatory profile includes:
| Regulatory issue |
Commercial impact |
| OTC monograph framework |
No conventional New Drug Application exclusivity is required for a compliant monograph product |
| Pseudoephedrine controls |
Behind-the-counter placement, purchase limits, identification requirements, and sales-record obligations |
| Labeling restrictions |
Required warnings for gastrointestinal bleeding, cardiovascular risk, hypertension, and contraindications |
| Combination-product compliance |
Each active ingredient and the combination must comply with applicable OTC requirements |
| Seasonal demand |
Higher volume during cold and influenza seasons |
The FDA’s review of oral phenylephrine does not directly invalidate pseudoephedrine-based Advil Cold and Sinus products. FDA action concerning oral phenylephrine relates to the effectiveness of phenylephrine as a nasal decongestant, not to pseudoephedrine. [2]
What patents protect Advil Cold and Sinus?
No meaningful U.S. patent exclusivity appears to protect the basic commercial combination of ibuprofen and pseudoephedrine hydrochloride. Both active ingredients are long-established generic compounds.
The relevant protection profile is:
| Protection type |
Status |
| Active-ingredient patent |
Expired or commercially irrelevant |
| Orange Book listing |
Not generally applicable to this OTC monograph product |
| FDA prescription exclusivity |
None |
| Biosimilar exclusivity |
Not applicable |
| Formulation patents |
Possible historically, but unlikely to block ordinary generic combinations |
| Manufacturing patents |
Limited practical relevance for standard tablets or liquid gels |
| Trademark protection |
Advil and related trade dress remain commercially important |
| Regulatory compliance |
A continuing barrier to lawful sale, but not market exclusivity |
The commercial moat is therefore brand and distribution rather than patent exclusivity. Generic manufacturers can sell ibuprofen-pseudoephedrine combinations if their products comply with FDA requirements and applicable state controls.
When does Advil Cold and Sinus lose exclusivity?
Advil Cold and Sinus does not have a conventional future patent-expiration event comparable to a prescription drug facing generic entry. Its active ingredients have been available for decades, and competing OTC products already exist.
The relevant timeline is:
| Period |
Event |
| Before 1980s |
Ibuprofen and pseudoephedrine become established OTC ingredients |
| 1980s-1990s |
Combination cold and sinus products expand across U.S. retail channels |
| 2006 onward |
Federal pseudoephedrine sales controls materially change retail access |
| 2022 |
Advil transfers to Haleon as part of the GSK consumer-health separation |
| 2023 onward |
FDA scrutiny of oral phenylephrine increases attention to decongestant efficacy |
| Current |
Competition is driven by brand, pricing, retailer placement, and supply availability |
There is no single “loss of exclusivity” date. Generic and private-label competition is already structurally present.
How strong is the Advil Cold and Sinus patent estate?
The patent estate is weak as a barrier to generic entry but stronger as a brand-protection platform.
Composition and formulation protection
The active ingredients are old, inexpensive, and widely manufactured. A competitor can generally reproduce the pharmacological concept without infringing a live compound patent. Potential formulation claims could cover specific release profiles, capsule technologies, excipient combinations, or manufacturing processes, but ordinary immediate-release products face limited technical barriers.
Trademark and trade dress
The Advil name has greater commercial value than the underlying formulation IP. Trademark protection can restrict confusingly similar branding, packaging, and consumer presentation. It cannot prevent sale of a therapeutically equivalent ibuprofen-pseudoephedrine product under a different name.
Manufacturing barriers
Manufacturing requirements are modest compared with biologics or complex drug-delivery systems. The main barriers are:
- Controlled procurement and distribution of pseudoephedrine.
- FDA-compliant facilities and quality systems.
- Supply-chain management for ibuprofen and pseudoephedrine.
- Retail authorization and shelf placement.
- State-by-state compliance with pseudoephedrine laws.
The manufacturing barrier is operational, not patent-based.
Are there Paragraph IV challenges to Advil Cold and Sinus?
Paragraph IV litigation is generally not the relevant competitive mechanism because Advil Cold and Sinus is an OTC product rather than a conventional Orange Book-listed prescription drug.
A generic company does not normally need to file an ANDA Paragraph IV certification against a listed Advil Cold and Sinus patent to market a compliant monograph product. Market entry instead occurs through OTC regulatory compliance, private-label contracting, and retail distribution.
The likely legal disputes are trademark, false advertising, packaging, product liability, or regulatory-compliance cases rather than Hatch-Waxman patent litigation.
What generic entry risks affect Advil Cold and Sinus?
Generic entry risk is high in product availability and low in legal complexity.
Private-label substitution
Retailers can sell store-brand ibuprofen-pseudoephedrine products at lower prices. Private-label products are particularly competitive when consumers seek a known active-ingredient combination rather than a specific brand.
Pharmacy substitution
Pharmacists and consumers can recommend lower-cost alternatives. Since pseudoephedrine products are often stored behind the pharmacy counter, the retailer controls visibility and staff recommendation.
Price compression
Retailers can use store brands to pressure branded manufacturers on wholesale pricing, promotions, and shelf allocation. The effect is strongest outside periods of acute seasonal demand.
Brand resilience
Advil benefits from high consumer awareness and a long history in pain relief. That supports a price premium, but the premium is vulnerable when inflation raises household spending pressure or retailers expand private-label offerings.
Which companies challenge Advil Cold and Sinus?
Competition comes from branded, generic, and retailer-owned products rather than a single patent challenger.
| Competitor category |
Representative products or companies |
Competitive advantage |
| Branded ibuprofen combinations |
Motrin and other legacy brands |
Established analgesic recognition |
| Acetaminophen combinations |
Tylenol Cold & Sinus |
Strong acetaminophen brand equity |
| Pseudoephedrine brands |
Sudafed |
Decongestant-specific recognition |
| Retailer private labels |
CVS, Walgreens, Walmart, Kroger, Costco brands |
Lower price and retailer control |
| Generic manufacturers |
Perrigo, Teva, store-brand suppliers, contract manufacturers |
Low-cost supply |
| Single-ingredient products |
Advil, ibuprofen generics, Sudafed |
Consumer flexibility and lower price |
The most direct competitor is a lower-priced ibuprofen-pseudoephedrine equivalent. Sudafed also competes for consumers who prioritize congestion relief and are willing to purchase the ingredients separately.
How do pseudoephedrine restrictions affect market dynamics?
Pseudoephedrine controls are one of the product’s most important commercial constraints. Federal law requires retailers to place nonprescription pseudoephedrine products behind the counter or in controlled-access areas and imposes daily and monthly purchase limits. Electronic tracking and identification requirements add operational friction. [3]
These controls affect:
- Store availability.
- Pharmacy labor requirements.
- Consumer convenience.
- Product visibility.
- Retailer willingness to stock multiple package sizes.
- Online fulfillment and delivery models.
The restrictions can also protect established brands with reliable pharmacy distribution. Smaller brands may face greater difficulty securing retailer support because controlled-counter placement limits shelf capacity.
What are the financial drivers for Advil Cold and Sinus?
Haleon’s financial trajectory for Advil Cold and Sinus is driven by volume, price, product mix, seasonality, and retailer inventory decisions.
| Financial driver |
Expected effect |
| Price increases |
Supports nominal revenue but can accelerate private-label switching |
| Cold and influenza severity |
Increases seasonal demand |
| Respiratory-season timing |
Shifts revenue between quarters |
| Retail promotions |
Increases unit volume but reduces net price |
| Private-label penetration |
Pressures market share and margins |
| Pseudoephedrine supply |
Can constrain distribution |
| E-commerce growth |
Improves search visibility but increases price transparency |
| Brand investment |
Supports awareness but raises selling expense |
Advil Cold and Sinus has a relatively favorable gross-margin profile because the active ingredients are inexpensive. Margin pressure comes from trade promotions, retailer bargaining power, packaging, compliance, logistics, and advertising.
Haleon’s broader financial performance is exposed to foreign exchange, input costs, retailer inventory normalization, consumer trade-down, and changing respiratory demand. Product-level revenue cannot be isolated from public company filings. [1]
How does Advil Cold and Sinus compare with competing cold medicines?
| Product type |
Main strength |
Main weakness |
| Advil Cold and Sinus |
Combines pain relief with pseudoephedrine decongestion |
Behind-counter access and ibuprofen contraindications |
| Tylenol Cold & Sinus |
Strong acetaminophen brand and broad product range |
Acetaminophen dosing and liver-risk warnings |
| Sudafed |
Strong congestion-relief positioning |
Does not necessarily provide comparable analgesic benefit |
| Generic ibuprofen-pseudoephedrine |
Low price |
Less brand recognition |
| Phenylephrine combinations |
Broad retail availability in some formats |
FDA effectiveness concerns regarding oral phenylephrine |
| Separate ibuprofen plus pseudoephedrine |
Flexible dosing |
Less convenience and potentially higher transaction friction |
The product’s strongest consumer proposition is convenience: one purchase delivers analgesic and decongestant treatment. Its main weakness is that pseudoephedrine regulation makes the purchase less convenient than ordinary OTC pain relievers.
What licensing deals and biosimilar risks apply?
No major product-specific licensing transaction or biosimilar threat is central to Advil Cold and Sinus. The product is a conventional small-molecule OTC combination, not a biologic.
Licensing risk is limited because the formulation does not depend on a proprietary biologic platform, device, or specialized delivery system. Commercial agreements are more likely to involve manufacturing, distribution, private-label supply, or retailer arrangements than rights to a protected pharmaceutical technology.
What generic launch scenarios are most likely?
The principal launch scenarios are:
- Continued branded premium with stable seasonal demand.
- Retailer expansion of private-label ibuprofen-pseudoephedrine products.
- Consumer trade-down during periods of inflation.
- Greater use of separate single-ingredient products.
- Retail-channel disruption caused by pseudoephedrine controls or supply shortages.
- Product reformulation or packaging changes in response to regulatory developments.
A conventional patent cliff is unlikely. The more realistic risk is gradual share erosion, with branded demand remaining strongest among consumers who value Advil recognition or prefer a known combination.
Key Takeaways
- Advil Cold and Sinus combines ibuprofen and pseudoephedrine hydrochloride.
- Haleon owns and commercializes the Advil brand.
- Haleon does not separately disclose Advil Cold and Sinus revenue.
- The product has no material Orange Book or biosimilar exclusivity profile.
- Generic and private-label competition is already established.
- Pseudoephedrine controls are a major distribution and convenience constraint.
- The commercial moat is brand equity, retailer access, and consumer trust.
- Financial performance depends on seasonal respiratory demand, pricing, promotions, and private-label penetration.
- The principal legal risks are regulatory, trademark, labeling, and product-liability issues rather than Paragraph IV patent litigation.
- No conventional patent-expiration event is expected to create a sudden generic cliff.
FAQs
Is Advil Cold and Sinus a prescription drug?
No. It is an OTC product containing established nonprescription active ingredients.
Can consumers buy Advil Cold and Sinus online?
Availability depends on retailer policies and applicable federal and state pseudoephedrine controls. Online sales may require identity verification, purchase-limit screening, and controlled fulfillment.
Does Advil Cold and Sinus have a biosimilar competitor?
No. Biosimilar law applies to biologic products, while Advil Cold and Sinus is a conventional small-molecule OTC combination.
Is pseudoephedrine in Advil Cold and Sinus more effective than oral phenylephrine?
Pseudoephedrine has a longstanding role as an oral nasal decongestant. FDA has separately questioned the effectiveness of oral phenylephrine at the labeled OTC dose. [2]
Does a generic ibuprofen-pseudoephedrine product infringe Advil patents?
A compliant generic product would not normally face an Advil composition patent barrier because the active ingredients are established compounds. Trademark and packaging restrictions remain relevant.
References
-
Haleon plc. (2024). Annual report and financial statements 2023. Haleon.
-
U.S. Food and Drug Administration. (2023). FDA proposes to remove oral phenylephrine from the OTC monograph. U.S. Department of Health and Human Services.
-
U.S. Drug Enforcement Administration. (2024). Pseudoephedrine and federal retail sales requirements. U.S. Department of Justice.
-
U.S. Food and Drug Administration. (2024). OTC monograph M012: Internal analgesic, antipyretic, and antirheumatic drug products. U.S. Department of Health and Human Services.
-
DailyMed. (2024). Advil Cold and Sinus product labeling. National Library of Medicine.
